Analyses
pericarditis
DISEASE, PERICARDITIS
This post hoc analysis evaluated path and time to rilonacept monotherapy in a group of patients who were receiving combination therapy with NSAIDs, colchicine, and/or glucocorticoids at baseline and who achieved rilonacept monotherapy during the run-in period. Of the 86 subjects that enrolled in the trial, 64% (n=55) entered on multidrug regimens. An ad hoc analysis was performed to assess the length of time necessary to achieve monotherapy. Patients were divided into three groups based on type of combination therapy: NSAID and colchicine double therapy; colchicine and glucocorticoid double therapy; and NSAID, colchicine and glucocorticoid triple therapy. Time to rilonacept monotherapy was also evaluated in patients with long-term (≥28 days) glucocorticoid treatment, with or without other pericarditis treatments, and in subgroups based on glucocorticoid dose (≤15 mg/day (median study dose) or >median study dose), annualised incidence (<2 episodes, 2–4 episodes, or >4 episodes) and disease duration (<1 year, 1–2 years, or >2 years). In patients receiving treatment with both colchicine and glucocorticoids, time to rilonacept monotherapy was assessed in subgroups stratified by taper approach. Those who completed tapering of glucocorticoid prior to beginning colchicine dose reduction/discontinuation were considered to have a ‘sequential’ taper. Those who began colchicine dose reduction/discontinuation during glucocorticoid taper were considered to have a ‘concurrent’ taper. Although sample size is small in this study, the mean was close to median for most continuous variables. In general, continuous variables are presented with descriptive mean and SD. In case mean deviates dramatically from median, median (Q1, Q3) is presented. For time to monotherapy, descriptive statistic is summarised and median (Q1, Q3) is presented.